Author:
Siwan Deepali,Nandave Mukesh,Kumar Anoop
Publisher
Springer Nature Singapore
Reference43 articles.
1. Alvarez Y, Hidalgo A, Maignen F, Slattery J (2010) Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling. Drug Saf 33:475–487
2. Anon (2022) 2022 Annual report on EudraVigilance for the European Parliament, the Council and the Commission. https://www.ema.europa.eu/en/documents/report/2022-annual-report-eudravigilance-european-parliament-council-commission_en.pdf. Accessed on 23 Sept 2023
3. Arlett P, Portier G, De Lisa R, Blake K, Wathion N, Dogne JM, Spooner A, Raine J, Rasi G (2014) Proactively managing the risk of marketed drugs: experience with the EMA pharmacovigilance risk assessment committee. Nat Rev Drug Discov 13(5):395–397
4. Arora A, Jalali RK, Vohora D (2017) Relevance of the weber effect in contemporary pharmacovigilance of oncology drugs. Ther Clin Risk Manag 11:1195–1203
5. Baldo P, De Paoli P (2014) Pharmacovigilance in oncology: evaluation of current practice and future perspectives. J Eval Clin Pract 20(5):559–569